The Karnataka Food and Drug Administration (FDA) and the United States Food and Drug Administration (US FDA) have reinforced their regulatory collaboration following a strategic meeting in Bengaluru aimed at strengthening food and drug regulation, enhancing manufacturing compliance and promoting public health through global best practices.

The meeting brought together senior officials from the US FDA India Office and the Karnataka FDA to discuss regulatory innovation, quality assurance, inspection systems and capacity-building initiatives designed to align Karnataka's regulatory framework with international standards.

The US FDA delegation comprised Greg Smith, Country Director; Dr. Jacquin Jones, International Relations Specialist; and Dhruv Shah, Senior Technical Advisor. The Karnataka FDA delegation was led by Srinivas K, Commissioner, along with Vijaya E. Ravikumar, Joint Commissioner; Dr. Umesh S., Additional Drugs Controller; Dr. B.R. Jagashetty, former National Adviser (Drugs Control) to the Ministry of Health and Family Welfare and CDSCO, and former Karnataka Drugs Controller; Dr. Bhaskaran, Headquarters Deputy Drugs Controller; and Dr. Kempaiah Suresh, Headquarters Deputy Drugs Controller.

During the discussions, both regulatory authorities agreed on several strategic initiatives to strengthen oversight and improve compliance across the pharmaceutical and food sectors. A key focus was the implementation of educational enforcement programmes, combining technical training with robust regulatory enforcement to encourage greater industry compliance.

The two agencies also explored the introduction of an Observer Programme, under which Karnataka FDA inspectors would participate as observers during future US FDA inspections of manufacturing facilities within the state. The initiative is expected to provide inspectors with first-hand exposure to internationally recognised regulatory practices.

In addition, both sides proposed organising joint training workshops for regulators and pharmaceutical manufacturers covering critical areas such as Good Manufacturing Practices (GMP), data integrity, Corrective and Preventive Actions (CAPA), quality systems and advanced laboratory controls. Discussions also included establishing an annual Karnataka–US FDA Regulatory Collaboration Forum to review emerging global compliance trends and regulatory developments.

To institutionalise the partnership, Karnataka FDA proposed the creation of a dedicated US FDA Coordination Cell that would oversee training programmes, observer placements and follow-up activities arising from the collaboration.

According to the Karnataka FDA, the visiting US FDA delegation appreciated the state's ongoing regulatory reforms aimed at strengthening manufacturing compliance, improving product quality and safeguarding public health.

Commenting on the collaboration, Srinivas K, Commissioner of Karnataka FDA, said the exchange of technical expertise and global regulatory insights would significantly enhance the capabilities of the state's regulatory workforce while helping ensure that products manufactured in Karnataka continue to meet international quality standards.

The collaboration marks another milestone in the US FDA's engagement with Indian state regulators. Following similar partnerships with Telangana and Gujarat, Karnataka becomes the third Indian state to establish a structured regulatory collaboration with the US FDA.

India currently hosts approximately 750 US FDA-approved pharmaceutical manufacturing facilities, the highest number outside the United States. Karnataka alone is home to 49 US FDA-approved plants, including facilities operated by Biocon, Strides Pharma Science, OneSource Specialty Pharma, Micro Labs, Kemwell Biopharma, Viatris (formerly Mylan Laboratories), Jubilant Pharmova, Hikal, Cipla, Hetero, RL Fine Chem and Apotex Pharmachem India, underscoring the state's significant contribution to India's global pharmaceutical manufacturing ecosystem.